(Total Views: 617)
Posted On: 11/24/2021 5:15:19 PM
Post# of 154756
Ohm wrote,
I do believe that Kelly was pointing in a particular direction today. Kelly has said more than once that this will be "an oncology company" in the future. One of the follow up catalysts Ohm talks about could be that we designate non-oncology indications NASH and NAFLD for a US partnership. (1 in 4 Americans has NAFLD). Kelly said the NASH animal results were great, but you can't partner up w/ animal results only. Now we're getting good NASH results from the open label arm using 350 mg; I think the blinded portion, with 700 mg., will do better. Will partnership have to wait for a trial using biopsies? Maybe. Maybe not.
That partnership will set us up for many of Ohm's 62 indications. We'll soon have trials for every kind of solid tumor cancer, for Osteoarthritis and Alzheimer's, for Chronic Fatigue and stroke. The moon is, you know, close.
Quote:
What will... results from the NASH trial at 700mg do for the share price? We should have those in 6 weeks or so. Then a bunch of follow up catalysts.
I do believe that Kelly was pointing in a particular direction today. Kelly has said more than once that this will be "an oncology company" in the future. One of the follow up catalysts Ohm talks about could be that we designate non-oncology indications NASH and NAFLD for a US partnership. (1 in 4 Americans has NAFLD). Kelly said the NASH animal results were great, but you can't partner up w/ animal results only. Now we're getting good NASH results from the open label arm using 350 mg; I think the blinded portion, with 700 mg., will do better. Will partnership have to wait for a trial using biopsies? Maybe. Maybe not.
That partnership will set us up for many of Ohm's 62 indications. We'll soon have trials for every kind of solid tumor cancer, for Osteoarthritis and Alzheimer's, for Chronic Fatigue and stroke. The moon is, you know, close.
(14)
(0)
